SCHEMBL1572422

SCHEMBL1572422

COc1cccc(-c2scnc2C(=O)N2[C@H](CN)C[C@@H]3C[C@@H]32)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 7/20 0.40
HCRTR2 O43614 6/20 0.40
VHL P40337 1/20 0.39
NPC1 O15118 5/20 0.38
RAB9A P51151 5/20 0.38
ALDH1A1 P00352 3/20 0.38
HPGD P15428 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
TP53 P04637 2/20 0.38
TSHR P16473 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
HTT P42858 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
THPO P40225 1/20 0.37
LMNA P02545 1/20 0.37
PMP22 Q01453 1/20 0.37
CFD P00746 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1572417 0.86 HCRTR1 (0.41) HCRTR1HCRTR2VHLNPC1RAB9A
SCHEMBL1572419 0.86 HCRTR1 (0.41) HCRTR1HCRTR2VHLNPC1RAB9A
SCHEMBL1572594 0.86 HCRTR1 (0.42) HCRTR1HCRTR2CYP1A2CYP3A4THPO
SCHEMBL1764517 0.85 KDM4E (0.48) HCRTR1HCRTR2VHLCYP1A2CYP3A4
SCHEMBL1764519 0.85 KDM4E (0.48) HCRTR1HCRTR2VHLCYP1A2CYP3A4
SCHEMBL1571930 0.83 HCRTR2 (0.39) HCRTR1HCRTR2VHLNPC1RAB9A
SCHEMBL2127749 0.82 HCRTR1 (0.39) HCRTR1HCRTR2VHLNPC1RAB9A
SCHEMBL1571640 0.80 HCRTR1 (0.47) HCRTR1HCRTR2
SCHEMBL1571651 0.79 HCRTR2 (0.41) HCRTR1HCRTR2VHLNPC1RAB9A
SCHEMBL2635818 0.77 HCRTR1 (0.45) HCRTR1HCRTR2VHLNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288435-B2 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2012-10-16 US claimed
EP-2094690-B1 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2011-04-13 EP claimed
EP-2094690-A2 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2009-09-02 EP claimed
WO-2008081399-A2 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2008-07-10 WO claimed
US-8288435-B2 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2012-10-16 US disclosed
EP-2094690-A2 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2009-09-02 EP disclosed
WO-2008081399-A2 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2008-07-10 WO disclosed